OncoHost is empowering oncology care with precision diagnostics
OncoHost’s PROphet® platform uses bioinformatic proteomic pattern recognition and AI to generate a personalized PROphet® score. This score predicts the benefit of PD-1/PD-L1 inhibitors, aiding in clinical decision-making with the goal of improving patient outcomes. Providing an all-inclusive evaluation of the tumor and host microenvironment, the test is performed on plasma or serum samples prior to initiation of treatment.
Understanding the interplay between
Cancer, Patient & Therapy
A new dimension to personalization
Watch now
A new approach to managing PD-1/PD-L1 inhibitor therapeutic strategies
Blood-based test
Personalized
PROphet® Report
Predictive
clinical insights
Clinical evidence-
based treatment considerations
Learn more about PROphet® in this ISLB webinar featuring:
Prof. David Gandara
Prof. David Carbone
Plasma Proteomic
Pattern Recognition
Analyzing the biological interplay between the patient, tumor, and therapy can:
Enable early prediction of clinical benefit from PD-1/PD-L1 inhibitors
Provide actionable clinical insights and optimal therapy choices
Read more
.png)
.png)
